Passage Bio (PASG) Stock Forecast, Price Target & Predictions
PASG Stock Forecast
Passage Bio stock forecast is as follows: an average price target of $6.00 (represents a 794.99% upside from PASG’s last price of $0.67) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
PASG Price Target
The average price target for Passage Bio (PASG) is $6.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential 794.99% upside from PASG's last price of $0.67.
PASG Analyst Ratings
According to 6 Wall Street analysts, Passage Bio's rating consensus is 'Buy'. The analyst rating breakdown for PASG stock is 0 'Strong Buy' (0.00%), 5 'Buy' (83.33%), 1 'Hold' (16.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Passage Bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jan 19, 2022 | Madhu Kumar | Goldman Sachs | $6.00 | $4.94 | 21.46% | 794.99% |
The latest Passage Bio stock forecast, released on Jan 19, 2022 by Madhu Kumar from Goldman Sachs, set a price target of $6.00, which represents a 21.46% increase from the stock price at the time of the forecast ($4.94), and a 794.99% increase from PASG last price ($0.67).
Passage Bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $0.67 | $0.67 | $0.67 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Passage Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Passage Bio's last price of $0.67. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 17, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Sep 03, 2024 | Rodman & Renshaw | Buy | Initialise | |
| Nov 14, 2023 | Raymond James | Outperform | Outperform | Hold |
| Dec 15, 2022 | Chardan Capital | Buy | Buy | Hold |
| Nov 11, 2022 | Guggenheim | Buy | Buy | Hold |
| May 17, 2022 | Raymond James | Outperform | Outperform | Hold |
| Jan 19, 2022 | Goldman Sachs | Neutral | Downgrade |
Passage Bio's last stock rating was published by Canaccord Genuity on Sep 17, 2024. The company gave PASG a "Buy" rating, the same as its previous rate.
Passage Bio Financial Forecast
Passage Bio Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | $1.67M | - |
| High Forecast | - | - | - | - | - | $1.67M | - |
| Low Forecast | - | - | - | - | - | $1.67M | - |
| # Analysts | - | - | - | - | - | 3 | - |
| Surprise % | - | - | - | - | - | - | - |
Passage Bio's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. PASG's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Passage Bio EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 3 | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict PASG's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Passage Bio's previous annual EBITDA (undefined) of $NaN.
Passage Bio Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 3 | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-13.59M | $-13.59M | $-15.44M | $-15.44M | $-13.28M | $-14.32M | $-19.07M |
| High Forecast | $-13.59M | $-13.59M | $-15.44M | $-15.44M | $-12.01M | $-14.32M | $-19.07M |
| Low Forecast | $-13.59M | $-13.59M | $-15.44M | $-15.44M | $-14.54M | $-14.32M | $-19.07M |
| Surprise % | - | - | - | - | - | - | - |
Passage Bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PASG's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Passage Bio SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 3 | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Passage Bio's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to PASG last annual SG&A of $NaN (undefined).
Passage Bio EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 3 | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.22 | $-0.22 | $-0.25 | $-0.25 | $-0.21 | $-0.23 | $-0.31 |
| High Forecast | $-0.22 | $-0.22 | $-0.25 | $-0.25 | $-0.19 | $-0.23 | $-0.31 |
| Low Forecast | $-0.22 | $-0.22 | $-0.25 | $-0.25 | $-0.24 | $-0.23 | $-0.31 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Passage Bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PASG previous annual EPS of $NaN (undefined).